I

Inter Pharma PCL
SET:IP

Watchlist Manager
Inter Pharma PCL
SET:IP
Watchlist
Price: 4.16 THB 0.97% Market Closed
Market Cap: ฿2.5B

EV/IC

1
Current
13%
Cheaper
vs 3-y average of 1.1

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1
=
Enterprise Value
฿2.9B
/
Invested Capital
฿2.9B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1
=
Enterprise Value
฿2.9B
/
Invested Capital
฿2.9B

Valuation Scenarios

Inter Pharma PCL is trading below its 3-year average

If EV/IC returns to its 3-Year Average (1.1), the stock would be worth ฿4.78 (15% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-51%
Maximum Upside
+49%
Average Downside
1%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1 ฿4.16
0%
3-Year Average 1.1 ฿4.78
+15%
5-Year Average 1.4 ฿6.22
+49%
Industry Average 0.5 ฿2.04
-51%
Country Average 0.8 ฿3.41
-18%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
TH
Inter Pharma PCL
SET:IP
2.5B THB 1 35
FR
L'Oreal SA
PAR:OR
199.5B EUR 4.4 32.6
UK
Unilever PLC
LSE:ULVR
92.2B GBP 2.5 11.2
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.5T INR 9 37.7
UK
HALEON PLC
LSE:HLN
31.2B GBP 1.4 18.7
US
Estee Lauder Companies Inc
NYSE:EL
28B USD 2.1 -157.1
DE
Beiersdorf AG
XETRA:BEI
15.8B EUR 1.7 16.9
JP
Kao Corp
TSE:4452
2.7T JPY 1.9 22.4
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.1T INR 7.5 61.2
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD 13 371.8 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
800.1B INR 8 43.5
P/E Multiple
Earnings Growth PEG
TH
I
Inter Pharma PCL
SET:IP
Average P/E: 31
35
N/A N/A
FR
L'Oreal SA
PAR:OR
32.6
13%
2.5
UK
Unilever PLC
LSE:ULVR
11.2
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
37.7
7%
5.4
UK
HALEON PLC
LSE:HLN
18.7
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -157.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
16.9
6%
2.8
JP
Kao Corp
TSE:4452
22.4
10%
2.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
61.2
18%
3.4
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
43.5
11%
4

Market Distribution

In line with most companies in Thailand
Percentile
62nd
Based on 402 companies
62nd percentile
1
Low
0 — 0.6
Typical Range
0.6 — 1.2
High
1.2 —
Distribution Statistics
Thailand
Min 0
30th Percentile 0.6
Median 0.8
70th Percentile 1.2
Max 119.8

Inter Pharma PCL
Glance View

Market Cap
2.5B THB
Industry
Consumer products

Inter Pharma PCL is engaged in biopharmaceutical business. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2019-11-05. The firm is principally engaged in the importing, manufacturing and distribution of dietary supplement product for humans and animals. The firm provides wellness and anti-aging products, aesthetic innovation products, animal health products and livestock products. Its wellness and anti-aging products include Probac7, Probac10 plus, TS6, Beta Glucan Plus, Pure Krill Oil, Astacurmin and YUUU Cleansing Mousse. Its aesthetic innovation products include Perfectha Complement, Perfectha Derm, Perfectha Deep and Perfectha Subskin. The Company’s animal health products include Dr.Choice Cal-B, Dr.Choice Cardi-B, Petinol, Pet Select Senior, Pet Select Osteoflex and Malaseb Shampoo for dogs and cats. The company also offers pet foods for dogs and cats. Its subsidiaries include Inter Vetta Co., Ltd., Modern Pharma Co., Ltd. and Inter Petrina Co., Ltd.

IP Intrinsic Value
2.63 THB
Overvaluation 37%
Intrinsic Value
Price ฿4.16
I
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett